Compositions and Methods Comprising Glycyl-Trna Synthetases Having Non-Canonical Biological Activities
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application 61/095,548, filed Sep 9, 2008. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,747,840 | Compositions and Methods Comprising Glycyl-Trna Synthetases Having Non-Canonical Biological Activities In force · High confidence | Atyr Pharma Inc. | In force | High confidence | ||
| US 9,157,076 | Compositions and Methods Comprising Glycyl-Trna Synthetases Having Non-Canonical Biological Activities In force · High confidence | Atyr Pharma, Inc. | In force | High confidence | ||
| US 9,585,946 | Compositions and Methods Comprising Glycyl-Trna Synthetases Having Non-Canonical Biological Activities In force · High confidence | Atyr Pharma, Inc. | In force | High confidence | ||
| US 8,404,471 | Compositions and Methods Comprising Glycyl-Trna Synthetases Having Non-Canonical Biological Activities In force · High confidence | Atyr Pharma, Inc. | In force | High confidence | ||
| Application 15/415,328 | Compositions and Methods Comprising Glycyl-Trna Synthetases Having Non-Canonical Biological Activities Abandoned Abandoned Apr 6, 2019 | Atyr Pharma, Inc. | Abandoned | Abandoned Apr 6, 2019 |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Atyr Pharma, Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.